BioCardia appointed Ian McNiece, PhD, as chief scientific officer of the company. Dr. McNiece has spent 30 years in both academic and commercial settings working in the areas of stem cell biology and clinical manufacturing for bone marrow transplantation and cellular therapy clinical applications. Dr. McNiece has been a collaborator with the company since 2007, directing manufacturing of stem cell products and clinical, manufacturing and control (CMC) development for several important clinical trials co-sponsored by the company, including TAC-HFT and POSEIDON.